Results 21 to 30 of about 9,741 (153)

Variability of response on prophylactic prasugrel for endovascular treatment of intracranial aneurysms: Clinical implications.

PLoS ONE, 2023
Background and purposeProphylactic prasugrel for endovascular treatment of intracranial aneurysms has been introduced and increased, but HTPR (high on-treatment platelet reactivity) or LTPR (low on-treatment platelet reactivity) of prasugrel is not ...
Noah Hong, Seung Bin Kim, Hee-Jin Yang, Young-Je Son   +3 more
doaj   +1 more source

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Management of patients with non–ST‐segment–elevation acute coronary syndrome (NSTE‐ACS) is based on 2020 European Society of Cardiology guidelines, which recommend the preferential use of prasugrel over ticagrelor. Because the selection of the
Mustafa Yildirim, Matthias Mueller‐Hennessen, Barbara Ruth Milles, Moritz Biener, Hauke Hund, Norbert Frey, Evangelos Giannitsis, Christian Salbach   +7 more
doaj   +1 more source

Eversion endarterectomy under full prasugrel treatment

SAGE Open Medical Case Reports, 2017
The third-generation thienopyridine prasugrel has much stronger antiplatelet effect compared to other current antiplatelet inhibitors and exhibits practically zero resistance in healthy people.
Thomas Kotsis, Panagitsa Christoforou, Nikolaos Asaloumidis, Erifyli Argyra   +3 more
doaj   +1 more source

Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

Marshall Journal of Medicine, 2019
Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI.
Ahmed Amro, Kanaan Mansoor, Mohammad Amro, Amal Sobeih, Obadah Aqtash, Hisham Hirzallah, Alaa Gabi , Madhulika Urella, Waseem Ahmed , Sandra Shenouda, Rameez Sayyed   +10 more
doaj   +1 more source

Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication

Haematologica, 2015
In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor like prasugrel is prescribed for one year. Here, we investigated how the hemostatic function of platelets recovers after discontinuation of prasugrel ...
Constance C. F. M. J. Baaten, Leo F. Veenstra, Rick Wetzels, Johanna P. van Geffen, Frauke Swieringa, Susanne M. de Witt, Yvonne M. C. Henskens, Harry Crijns, Sven Nylander, J. J. J. van Giezen, Johan W. M. Heemskerk, Paola E. J. van der Meijden   +11 more
doaj   +1 more source

Dual Artery Compression for Patent Hemostasis and Prevention of Radial Artery Occlusion: The Quebec Terry2 Registry

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Radial artery occlusion (RAO) is a common complication following transradial artery access (TRA). Patent hemostasis is recommended to reduce RAO. Prophylactic ulnar artery compression is a technique to increase the rate of patent hemostasis.
Tomas A. Cieza, Francis Bonnenfant, Jimmy MacHaalany, Paola Ulacia‐Flores, Safia Ouarrak, Andres Ruhl, Erika Pomerleau, Joany Lapierre, Olivier F. Bertrand   +8 more
wiley   +1 more source

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

Journal of Hematology & Oncology, 2013
Background Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients with SCD ...
Wun Ted, Soulieres Denis, Frelinger Andrew L, Krishnamurti Lakshmanan, Novelli Enrico M, Kutlar Abdullah, Ataga Kenneth I, Knupp Charles L, McMahon Lillian E, Strouse John J, Zhou Chunmei, Heath Lori E, Nwachuku Chuke E, Jakubowski Joseph A, Riesmeyer Jeffrey S, Winters Kenneth J   +15 more
doaj   +1 more source

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?

Рациональная фармакотерапия в кардиологии, 2020
Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment. The new generation of inhibitors of P2Y12 platelet receptors (prasugrel and ticagrelor) provide more pronounced platelet inhibition than clopidogrel.
T. M. Uskach, A. S. Tereshchenko
doaj   +1 more source

Effects of Clopidogrel, Prasugrel and Ticagrelor on Microvascular Function and Platelet Reactivity in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Stenting. A Randomized, Blinded, Parallel Group Trial

Frontiers in Cardiovascular Medicine, 2021
Aims: In this pre-specified analysis of the “endothelium, stent and antiplatelet therapy” study, we investigate the impact of antiplatelet therapies on microvascular function in patients undergoing stenting for an acute coronary syndrome.Methods and ...
Boris Schnorbus, Boris Schnorbus, Kerstin Jurk, Karl J. Lackner, Caroline Welk, Thomas Münzel, Tommaso Gori, Tommaso Gori   +7 more
doaj   +1 more source

The Prognostic Impact of Multiple Adverse Events on Long‐Term Mortality Following Acute Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Adverse events after acute myocardial infarction (AMI) are individually associated with poor outcomes, but the prognostic impact of the overlap of different event types occurring sequentially within the same patient remains uncertain.
Kyung Hoon Roh, Yong Hee Kim, Eun Ho Choo, Kwan Yong Lee, Ik Jun Choi, Jong‐Min Lee, Ki‐Dong Yoo, Mahn‐Won Park, Chul Soo Park, Hee‐Yeol Kim, Min Chul Kim, Youngkeun Ahn, Kiyuk Chang   +12 more
wiley   +1 more source